Granted Patent
B2
US 12,721,914 · App. 18/049,609 · Granted Sep 1, 2026
Radiolabeled anti-LAG3 antibodies for immuno-PET imaging
Inventors:
Marcus Kelly (New York, NY); Dangshe Ma (Pleasantville, NY); William Olson (Yorktown Heights, NY); Gavin Thurston (Millerton, NY); Richard Tavare (Salt Lake City, UT)
Assignee:
Regeneron Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Radiolabeled anti-LAG3 antibodies and their use in immuno-PET imaging are provided herein. Included are methods of detecting the presence of LAG3 proteins in a patient or sample.
Claims (23)
1 . A method for identifying a candidate for anti-tumor therapy, the method comprising:
(i) administering a radiolabeled anti-LAG3 antibody conjugate to a patient with a solid tumor, wherein the radiolabeled anti-LAG3 antibody conjugate comprises an anti-LAG3 antibody or antigen-binding fragment thereof comprising:
three heavy chain complementarity determining regions (HCDRs) in a heavy chain variable region (HCVR), wherein the HCVR has an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, 50, 66, 82, 98, 130, 146, 162, 178, 194, 210, 226, 242, 258, 274, 290, 322, 338, 354, 370, 386, 402, 418, 434, 458, 466, 474, 482, 490, 498, 506, 514, 538, and 554; and three light chain complementarity determining regions (LCDRs) in a light chain variable region (LCVR), wherein the LCVR has an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 42, 58, 74, 90, 106, 122, 138, 154, 170, 186, 202, 218, 234, 250, 266, 282, 298, 314, 330, 346, 362, 378, 394, 410, 426, 442, 522, 530, 546, and 562;
(ii) visualizing LAG3 expression by positron emission tomography (PET) imaging,
wherein presence of the radiolabeled antibody conjugate in the tumor identifies the patient as a candidate for anti-tumor therapy.
2 . The method of claim 1 , wherein the radiolabeled anti-LAG3 antibody conjugate comprises an anti-LAG3 antibody or antigen-binding fragment thereof, a chelating moiety, and a positron emitter.
3 . The method of claim 2 , wherein the antibody or antigen-binding fragment thereof is covalently bonded to one or more moieties of Formula (A):
-L-M Z (A)
wherein L is the chelating moiety; M is the positron emitter; and z, independently at each occurrence, is 0 or 1; and wherein at least one of z is 1.
4 . The method of claim 2 , wherein the chelating moiety comprises desferrioxamine.
5 . The method of claim 2 , wherein the positron emitter is 89 Zr.
6 . The method of claim 3 , wherein-L-Mis
wherein Zr is the positron emitter, 89 Zr.
7 . The method of claim 3 , wherein the antibody or antigen-binding fragment thereof is covalently bonded to one, two, or three moieties of Formula (A).
8 . The method of claim 2 , wherein the radiolabeled anti-LAG3 antibody conjugate comprises an antibody or antigen-binding fragment thereof having three heavy chain complementarity determining regions (HCDRs) and three light chain complementarity determining regions (LCDRs) within the heavy chain variable region (HCVR)/light chain variable region (LCVR) amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2/10, 18/26, 34/42, 50/58, 66/74, 82/90, 98/106, 130/138, 146/154, 162/170, 178/186, 194/202, 210/218, 226/234, 242/250, 258/266, 274/282, 290/298, 322/330, 338/346, 354/362, 370/378, 386/394, 402/410, 418/426, 434/442, 458/522, 466/522, 474/522, 482/522, 490/522, 498/530, 506/530, 514/530, 538/546, and 554/562.
9 . The method of claim 8 , wherein the radiolabeled anti-LAG3 antibody conjugate comprises an antibody or antigen-binding fragment thereof comprising a set of three HCDRs and three LCDRs, wherein the set of CDRs is selected from the group consisting of SEQ ID NOs: 4/6/8/12/14/16, 20/22/24/28/30/32, 36/38/40/44/46/48, 52/54/56/60/62/64, 68/70/72/76/78/80, 84/86/88/92/94/96, 100/102/104/108/110/112, 132/134/136/140/142/144, 148/150/152/156/158/160, 164/166/168/172/174/176, 180/182/184/188/190/192, 196/198/200/204/206/208, 212/214/216/220/222/224, 228/230/232/236/238/240, 244/246/248/252/254/256, 260/262/264/268/270/272, 276/278/280/284/286/288, 292/294/296/300/302/304, 324/326/328/332/334/336, 340/342/344/348/350/352, 356/358/360/364/366/368, 372/374/376/380/382/384, 388/390/392/396/398/400, 404/406/408/412/414/416, 420/422/424/428/430/432, 436/438/440/444/446/448, 460/462/464/524/526/528, 468/470/472/524/526/528, 476/478/480/524/526/528, 484/486/488/524/526/528, 492/494/496/524/526/528, 500/502/504/532/534/536, 508/510/512/532/534/536, 516/518/520/532/534/536, 540/542/544/548/550/552, and 556/558/560/564/566/568, respectively.
10 . The method of claim 2 , wherein the radiolabeled anti-LAG3 antibody conjugate comprises an antibody or antigen-binding fragment thereof having three HCDRs in an HCVR of SEQ ID NO: 418; and three LCDRs in an LCVR of SEQ ID NO: 426.
11 . The method of claim 2 , wherein the radiolabeled anti-LAG3 antibody conjugate comprises an antibody or antigen-binding fragment thereof having an HCDR1 amino acid sequence comprising SEQ ID NO: 420; an HCDR2 amino acid sequence comprising SEQ ID NO: 422; and an HCDR3 amino acid sequence comprising SEQ ID NO: 424; an LCDR1 amino acid sequence comprising SEQ ID NO: 428; an LCDR2 amino acid sequence comprising SEQ ID NO: 430; and an LCDR3 amino acid sequence comprising SEQ ID NO: 432.
12 . The method of claim 1 , wherein the radiolabeled anti-LAG3 antibody conjugate is administered at a dose of about 20 mg or less.
13 . The method of claim 1 , wherein the anti-tumor therapy is selected from nivolumab, ipilimumab, pembrolizumab, and combinations thereof.
14 . The method of claim 1 , wherein the anti-tumor therapy is a LAG3 inhibitor.
15 . The method of claim 1 , wherein the anti-tumor therapy is an anti-LAG3 antibody.
16 . The method of claim 15 , wherein the anti-tumor therapy is an anti-LAG3 antibody or antigen-binding fragment thereof that binds specifically to LAG3 and comprises three heavy chain complementarity determining regions (HCDRs) and three light chain complementarity determining regions (LCDRs) within the heavy chain variable region (HCVR)/light chain variable region (LCVR) amino acid sequence pair, wherein the HCVR/LCVR amino acid sequence pair is selected from the group consisting of SEQ ID NOS: 2/10, 18/26, 34/42, 50/58, 66/74, 82/90, 98/106, 114/122, 130/138, 146/154, 162/170, 178/186, 194/202, 210/218, 226/234, 242/250, 258/266, 274/282, 290/298, 306/314, 322/330, 338/346, 354/362, 370/378, 386/394, 402/410, 418/426, 434/442, 450/522, 458/522, 466/522, 474/522, 482/522, 490/522, 498/530, 506/530, 514/530, 538/546, and 554/562.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 12, 2025
From: KELLY, MARCUS; MA, DANGSHE; OLSON, WILLIAM; THURSTON, GAVIN; TAVARE, RICHARD
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 072882/0793 →
Continuity (4)
Provisional Application
62457287
· Feb 10, 2017
References Cited (341)
US 4680338A
· Sundoro
· 1987
[cited by applicant]
US 5332567A
· Goldenberg
· 1994
[cited by applicant]
US 5639879A
· Mease et al.
· 1997
[cited by applicant]
US 5976877A
· Hercend et al.
· 1999
[cited by applicant]
US 6143273A
· Faure et al.
· 2000
[cited by applicant]
US 6197524B1
· Romagnani
· 2001
[cited by applicant]
US 6524802B1
· Lee et al.
· 2003
[cited by applicant]
US 6596541B2
· Murphy et al.
· 2003
[cited by applicant]
US 7087411B2
· Daly et al.
· 2006
[cited by applicant]
US 7582298B2
· Stevens et al.
· 2009
[cited by applicant]
US 8246995B2
· Dai et al.
· 2012
[cited by applicant]
US 8257740B1
· Sung et al.
· 2012
[cited by applicant]
US 8502018B2
· Murphy et al.
· 2013
[cited by applicant]
US 8551481B2
· Pardoll et al.
· 2013
[cited by applicant]
US 8771966B2
· Dennis et al.
· 2014
[cited by applicant]
US 9321832B2
· Tomlinson et al.
· 2016
[cited by applicant]
US 9429584B2
· Matsumura et al.
· 2016
[cited by applicant]
US 9475874B2
· Sawada et al.
· 2016
[cited by applicant]
US 9475875B2
· Kirshner et al.
· 2016
[cited by applicant]
US 9546206B2
· Ring et al.
· 2017
[cited by applicant]
US 20040018557A1
· Qu et al.
· 2004
[cited by applicant]
US 20040101920A1
· Radziejewski et al.
· 2004
[cited by applicant]
US 20080193376A1
· Tawakol et al.
· 2008
[cited by applicant]
US 20080260650A1
· Tawakol et al.
· 2008
[cited by applicant]
US 20090297439A1
· Comoglio et al.
· 2009
[cited by applicant]
US 20100111856A1
· Gill et al.
· 2010
[cited by applicant]
US 20100233183A1
· Triebel et al.
· 2010
[cited by applicant]
US 20110150892A1
· Thudium et al.
· 2011
[cited by applicant]
US 20140127226A1
· Pardoll et al.
· 2014
[cited by applicant]
US 20150191543A1
· Wu et al.
· 2015
[cited by applicant]
US 20160000946A1
· Cheng et al.
· 2016
[cited by applicant]
US 20170097333A1
· Bhagwat et al.
· 2017
[cited by applicant]
US 20170283442A1
· D'Souza et al.
· 2017
[cited by applicant]
US 20170290914A1
· Liang et al.
· 2017
[cited by applicant]
US 20180078662A1
· Agnew et al.
· 2018
[cited by applicant]
US 20220249659A1
· Kroog et al.
· 2022
[cited by applicant]
US 20230357446A1
· Smith et al.
· 2023
[cited by applicant]
US 20240166740A1
· Ullman et al.
· 2024
[cited by applicant]
US 20240299601A1
· Cheung et al.
· 2024
[cited by applicant]
US 20240376229A1
· Garg et al.
· 2024
[cited by applicant]
US 20240409637A1
· Giurleo et al.
· 2024
[cited by applicant]
US 20250179177A1
· Tang et al.
· 2025
[cited by applicant]
US 20250218540A1
· Lim et al.
· 2025
[cited by applicant]
EP 0510079B1
· 1999
[cited by applicant]
EP 0758383B1
· 2007
[cited by applicant]
EP 1897548B1
· 2013
[cited by applicant]
EP 2320940B1
· 2015
[cited by applicant]
EP 2954933A1
· 2015
[cited by applicant]
EP 3266465A1
· 2016
[cited by applicant]
EP 2142210B1
· 2016
[cited by applicant]
WO 199530750A2
· 1995
[cited by applicant]
WO 199703695A1
· 1997
[cited by applicant]
WO 199858059A1
· 1998
[cited by applicant]
WO 2004078928A2
· 2004
[cited by applicant]
WO 2005103081A2
· 2005
[cited by applicant]
WO 2008124467A1
· 2008
[cited by applicant]
WO 2008132601A1
· 2008
[cited by applicant]
WO 2010019570A2
· 2010
[cited by applicant]
WO 2011056983A1
· 2011
[cited by applicant]
WO 2011153346A1
· 2011
[cited by applicant]
WO 2012087962A2
· 2012
[cited by applicant]
WO 2013022782A1
· 2013
[cited by applicant]
WO 2013138696A1
· 2013
[cited by applicant]
WO 2013149159A1
· 2013
[cited by applicant]
WO 2013165940A1
· 2013
[cited by applicant]
WO 2013177055A2
· 2013
[cited by applicant]
WO 2014008218A1
· 2014
[cited by applicant]
WO 2014140180A1
· 2014
[cited by applicant]
WO 2014159087A1
· 2014
[cited by applicant]
WO 2014159835A1
· 2014
[cited by applicant]
WO 2014200969A2
· 2014
[cited by applicant]
WO 2014210064A1
· 2014
[cited by applicant]
WO 2015042246A1
· 2015
[cited by applicant]
WO 2015048312A1
· 2015
[cited by applicant]
WO 2015053871A2
· 2015
[cited by applicant]
WO 2015061209A1
· 2015
[cited by applicant]
WO 2015075445A1
· 2015
[cited by applicant]
WO 2015089344A1
· 2015
[cited by applicant]
WO 2015132602A1
· 2015
[cited by applicant]
WO 2015138920A1
· 2015
[cited by applicant]
WO 2015140212A1
· 2015
[cited by applicant]
WO 2015179658A2
· 2015
[cited by applicant]
WO 2015191715A1
· 2015
[cited by applicant]
WO 2015200119
· 2015
[cited by applicant]
WO 2016020502A1
· 2016
[cited by applicant]
WO 2016028672A1
· 2016
[cited by applicant]
WO 2016040723A1
· 2016
[cited by applicant]
WO 2016040724A1
· 2016
[cited by applicant]
WO 2016040868A1
· 2016
[cited by applicant]
WO 2016058056A1
· 2016
[cited by applicant]
WO 2016126858
· 2016
[cited by applicant]
WO 2016144873A2
· 2016
[cited by applicant]
WO 2016172010A1
· 2016
[cited by applicant]
WO 2016200782
· 2016
[cited by applicant]
WO 2017015560A2
· 2017
[cited by applicant]
WO 2017016497
· 2017
[cited by applicant]
WO 2017059397A1
· 2017
[cited by applicant]
WO 2017062888A1
· 2017
[cited by applicant]
WO 2017087589
· 2017
[cited by applicant]
WO 2017087826A1
· 2017
[cited by applicant]
WO 2017087901
· 2017
[cited by applicant]
WO 2017106129
· 2017
[cited by applicant]
WO 2017149143
· 2017
[cited by applicant]
WO 2017198741
· 2017
[cited by applicant]
WO 2017201111A1
· 2017
[cited by applicant]
WO 2017213494A1
· 2017
[cited by applicant]
WO 2017219995
· 2017
[cited by applicant]
WO 2017220569
· 2017
[cited by applicant]
WO 2017223565A1
· 2017
[cited by applicant]
WO 2018049083A1
· 2018
[cited by applicant]
WO 2018058125A1
· 2018
[cited by applicant]
WO 2018083705A1
· 2018
[cited by applicant]
WO 2018128664A2
· 2018
[cited by applicant]
WO 2018148476
· 2018
[cited by applicant]
WO 2018222718A1
· 2018
[cited by applicant]
Martin et al. (1989) “Modeling antibody hypervariable loops: A combined algorithm,” PNAS 86:9268-9272.
[cited by applicant]
Matsuzaki et al. (2010) “Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer,” PNAS 107(17):7875-7880.
[cited by applicant]
Maute et al. (2015) “Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging”, Proc Natl Acad Sci U S A, 112(47):E6506-E6514.
[cited by applicant]
Mindt et al. (2014) “Octadetante bifuntional chelating agent for Zr-89 based Imagining probes”, Technology Opportunity, Ref. No. UZ-15/736, 1 page.
[cited by applicant]
Miyazaki et al. (1996) “Independent Modes of Natural Killing Distinguished in Mice Lacking Lag3,” Science 272:405-408.
[cited by applicant]
Natarajan et al. (2015) “Novel Radiotracer for ImmunoPET Imaging of PD-1 Checkpoint Expression on Tumor Infiltrating Lymphocytes”, Bioconjug Chem, 26(10):2062-2069.
[cited by applicant]
NCT01968109 on Sep. 3, 2015, ClinicalTrials.gov Archive, Sep. 3, 2015, pp. 1-6, XP055328270, retrieved from the Internet: URL:https://clinicaltrials.gov/archive/NCT01968109/2015_09_03.
[cited by applicant]
NCT03780725 on Dec. 19, 2018, ClinicalTrials.gov Archive, “This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI…
[cited by applicant]
Needleman and Wunsch (1970) “A general method applicable to the search for similarities in the amino acid sequence of two proteins,” J. Mol. Biol. 48:443-453.
[cited by applicant]
Nguyen, et al. (2014) “Clinical blockade of PD1 and LAG3—potential mechanisms of action”, Nature Reviews Immunology, 15(1):45-56.
[cited by applicant]
Nijland et al. (2019) “Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution in Lymphoma Patients”, University Medical Center Groningen, ClinicalTrials.gov Identifier: NCT03850028, 11 …
[cited by applicant]
Nishino et al. (2013) “Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements,” Clin. Cancer Res. 19:3936-3943.
[cited by applicant]
Norde et al. (2012) “Coinhibitory molecules in hematologic malignancies: targets for therapeutic intervention,” Blood 120(4):728-736.
[cited by applicant]
Okamura et al. (2009) “CD4+ CD25− LAG3+ regulatory T cells controlled by the transcription factor Egr-2,” PNAS 106(33):13974-13979.
[cited by applicant]
Okamura et al. (2012) “Roles of LAG3 and EGR2 in regulatory T cells,” Ann. Rheum. Dis. 71: 196-i100. doi:10.1136/annrheumdis-2011-200588.
[cited by applicant]
Okamura et al. (2015) “TGF-b3-expressing CD4+ CD25− LAG3+ regulatory T cells control humoral immune responses,” Nature Communications 6:6329.
[cited by applicant]
Okazaki (2010) “PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice,” J. Exp. Med. 208(2):395-407.
[cited by applicant]
Oosting et al. (2015) “89Zr-Bevacizumab PET Visualizes Heterogeneous Tracer Accumulation in Tumor Lesions of Renal Cell Carcinoma Patients and Differential Effects of Antiangiogenic Treatment”, The Journal of Nuclear Me…
[cited by applicant]
Padlan et al. (1995) “Identification of specificity-determining residues in antibodies,” The FASEB Journal 9:133-139.
[cited by applicant]
Pandya et al. (2015) “Di-macrocyclic terephthalamide ligands as chelators for the PET radionuclide zirconium-89”, Chem Commun (Camb), 51(12):2301-2303.
[cited by applicant]
Pardol (2012) “Regulating the Regulators for Cancer Immunotherapy: LAG-3 Finally Catches Up,” LAG-3 Presentation.
[cited by applicant]
Pardoll (2012) “The blockade of immune checkpointsin cancer immunotherapy,” Nature Reviews Cancer 12:252-264.
[cited by applicant]
Patra, et al. (2014) “An octadentate bifunctional chelating agent for the development of stable zirconium-89 based molecular imaging probes”, Chem. Commun. 50:11523-11525.
[cited by applicant]
Pearson (1994) “Using the FASTA Program to Search Protein and DNA Sequence Databases,” Methods in Molecular Biology 24:307-331.
[cited by applicant]
Perez-Garcia (2014) “Orchestrating immune check-point blockade for cancerimmunotherapy in combinations,” Current Opinion in Immunology, Tumour Immunology 27:89-97.
[cited by applicant]
Perk et al. (2009) “p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging”, Eur. J. Nucl. Med. Mol Imaging, 37(2):2…
[cited by applicant]
Perk, et al. (2010) “p-Isothiocyanatobezyl desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging”, European Journal of Nuclear Medicine an…
[cited by applicant]
Petrik, et al. (2016) “In Vitro and In Vivo Comparison of SelectedGa-68 and Zr-89 Labelled Siderophores”, Mol. Imaging Biol., 18:344-352.
[cited by applicant]
Poirier, et al. (2011) “Antibody-mediated depletion of lymphocyte-activation gene-3 (LAG-3+)-activated T lymphocytes prevents delayed-type hypersensitivity in non-human primates,” British Society for Immunology, Clinica…
[cited by applicant]
Powell et al. (1998) “Compendium of excipients for parenteral formulations,” J. Pharm. Sci. Technol. 52:238-311.
[cited by applicant]
Price et al. (2014) “H6phospa-trastuzumab: bifunctional methylenephosphonate-based chelator with 89Zr, 111In and 177Lu”, Dalton Trans., 43(1):119-131.
[cited by applicant]
Reddy et al. (2000) “Elimination of Fc Receptor-Dependent Effector Functions of a Modified IgG4 Monoclonal Antibody to Human CD4,” J. Immunol. 164:1925-1933.
[cited by applicant]
Reineke (2004) “Antibody Epitope Mapping Using Arrays of Synthetic Peptides,” Methods Mol. Biol. 248:443-463.
[cited by applicant]
Roncarolo et al. (2014) “Tr1 Cells and the Counter-Regulation of Immunity: Natural Mechanisms and Therapeutic Applications,” Curr. Top. Microbiol. Immunol. 380: 39-68.
[cited by applicant]
Rouhani et al. (2015) “Roles of lymphatic endothelial cells expressing peripheral tissue antigens in CD4 T-cell tolerance induction,” Nature Communications 6:6771.
[cited by applicant]
Rudikoff, et al. (1982) “Single amino acid substitution altering antigen-binding specificity,” Proc. Natl. Acad. Sci. 79:1979-1983.
[cited by applicant]
Schumacher, et al. (2016) “Current Status: Site-Specific Antibody Drug Conjugates”, J. Clin. Immunol. 36(Suppl1):S100-S107.
[cited by applicant]
Sega et al. (2014) “Role of Lymphocyte Activation Gene-3 (Lag-3) in Conventional and Regulatory T Cell Function in Allogeneic Transplantation,” PLoS One 9(1):e86551.
[cited by applicant]
Shield et al. (2002) “Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human Fc RIII and Antibody-dependent Cellular Toxicity,” J. of Biol. Chem. 277(30):26733-26740.
[cited by applicant]
Shin and Ribas (2015) “The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?” Current Opinion in Immunology, Tumour Immunology 33:23-35.
[cited by applicant]
Sierro et al. (2011) “The CD4-like molecule LAG-3, biology and therapeutic applications,” Expert Opin. Ther. Targets 15(1):91-101.
[cited by applicant]
Sittig et al. (2013) “Clonal expansion of renal cell carcinoma-infiltrating T lymphocytes,” Landes Bioscience, OncoImmunology 2:9, e26014-1-10.
[cited by applicant]
Slizys and Widnersson (2016) “The new “Pet” on the block: radio imaging with Zirconium-89”, FPA Patent Attorneys, 5 pages.
[cited by applicant]
Smith and Waterman (1981) “Identification of common molecular subsequences,” J. Mol. Biol. 147:195-197.
[cited by applicant]
Sun et al. (2014) “Expression regulation of co-inhibitory molecules on human natural killer cells in response to cytokine stimulations,” Cytokine 65:33-41.
[cited by applicant]
Taube et al. (2015) “Differential expression of immune-regulatory genes associated with PD-L1 display in melanoma: Implications for PD-L1 pathway blockade,” Clin Cancer Res Published Online First May 5, 2015.
[cited by applicant]
Tavare et al. (2016) “An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy”, Cancer Research , 76(1):73-82.
[cited by applicant]
Thaventhiran et al. (2012) “T Cell Co-inhibitory Receptors: Functions and Signalling Mechanisms,” J. Clin. Cell Immunol. S12:004. doi:10.4172/2155-9899.S12-004.
[cited by applicant]
Tian et al. (2015) “The Upregulation of LAG-3 on T Cells Defines a Subpopulation with Functional Exhaustion and Correlates with Disease Progression in HIV-Infected Subjects,” J. Immunol. 194:3873-3882.
[cited by applicant]
Triebel (2003) “LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination,” Trends in Immunology 24(12): 619-622.
[cited by applicant]
Gagliani et al. (2013) “Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells,” Nature Medicine 19(6):739-746.
[cited by applicant]
Gautron, et al. (2014) “Enhanced suppressor function of TIM-3+FoxP3+ regulatory T cells,” Eur. J. Immunol. 44:2703-2711.
[cited by applicant]
Gebhart et al. (2015) “Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1); the Zephir trial”, Annals of On…
[cited by applicant]
GenBank Accession NP_002277.4.
[cited by applicant]
GenBank Accession NP_005182.1.
[cited by applicant]
Goldberg and Drake (2011) “LAG-3 in Cancer Immunotherapy,” LAG-3 Biology Review, 269-278.
[cited by applicant]
Goldrath et al. (1999) “Selecting and maintaining a diverse T-cell repertoire,” Nature 402:255-262.
[cited by applicant]
Gonnet et al. (1992) “Exhaustive Matching of the Entire Protein Sequence Database,” Science 256:1443-1445.
[cited by applicant]
Gros et al. (2014) “PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors,” J. of Clinical Investigation 125(5):2246-2259.
[cited by applicant]
Grosso (2009) “Functionally Distinct LAG-3 and PD-1 Subsets on Activated and Chronically Stimulated CD8 T Cells1,” J. Immunol. 182:6659-6669.
[cited by applicant]
Grosso et al. (2007) “LAG-3 regulates CD8+ T cell accumulation and effector function in murine self-and tumor-tolerance systems,” J. of Clinical Investigation 117(11):3383-3392.
[cited by applicant]
Hemon et al. (2011) “MHC Class II Engagement by Its Ligand LAG-3 (CD223) Contributes to Melanoma Resistance to Apoptosis,” J. Immunol. 186:5173-5183.
[cited by applicant]
Herbst et al. (2014) “Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients” Nature 515(7528):563-567.
[cited by applicant]
Heskamp et al. (2015) “Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies”, Cancer Res, 75(14):2928-2936.
[cited by applicant]
Higashikawa et al. (2014) “64Cu-DOTA-Anti-CTLA-4 mAb Enabled PET Visualization of CTLA-4 on the T-Cell Infiltrating Tumor Tissues”, PLoS One, 9(11):e109866, 8 pages.
[cited by applicant]
Hochleitner et al. (2000) “Characterization of a discontinuous epitope of the human immunodeficiency virus (HIV) core protein p24 by epitope excision and differential chemical modification followed by mass spectrometric…
[cited by applicant]
Huang et al. (2004) “Role of LAG-3 in Regulatory T Cells,” Immunity 21:503-513.
[cited by applicant]
Huang et al. (2015) “LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model,” Oncotarget, 6(29):27359-27377.
[cited by applicant]
Huard et al. (1994) “Cellular expression and tissue distribution of the humanLAG-3-encoded protein, an MHC class II ligand,” Immunogenetics 39: 213-217.
[cited by applicant]
Huard et al. (1996) “T cell major histocompatibility complex class II molecules down-regulate CD4+ T cell clone responses following LAG-3 binding,” Eur. J. Immunol. 26:1180-1186.
[cited by applicant]
Huard et al. (1997) “Characterization of the major histocompatibility complex class II binding site on LAG-3 protein,” PNAS 94:5744-5749.
[cited by applicant]
Huard, et al. (1995) “CD4/major histocompatibility complex class II interaction analyzed with CD4− and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins,” Eur. J. Immunol. 25:2718-2721.
[cited by applicant]
International Search Report and Written Opinion, PCT/US2018/017525, mailed Apr. 17, 2018, 14 pages.
[cited by applicant]
International Search Report and Written Opinion, received for PCT/US2016/056156, on Mar. 10, 2017, 23 pages.
[cited by applicant]
Invitation to Pay Additional Fees and, Where Applicable, Protest Fee, received for PCT/US2016/056156, on Jan. 10, 2017, 10pgs.
[cited by applicant]
Jackson, et al. (1995) “In Vitro Antibody Maturation Improvement of a High Affinity, Neutralizing Antibody Against IL-1 beta,” The Journal of Immunology 154:3310-3319.
[cited by applicant]
Jauw et al. (2016) “Immuno-PositronEmissionRob'sographywithZirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials?” Frontiers in Pharmacology, vol. 7, Article 131, 15 page…
[cited by applicant]
Jing et al. (2015) “Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma,” J. for Immuno. Therapy of Cancer 3:2 pp. 1-15.
[cited by applicant]
Junghans et al. (1990) “Anti-Tac-H, a Humanized Antibody to the Interleukin 2 Receptor with New Features for Immunotherapy in Malignant and Immune Disorders,” Cancer Research 50:1495-1502.
[cited by applicant]
Juno et al. (2015) “Elevated expression of LAG-3, but not PD-1, is associated with impaired iNKT cytokine production during chronic HIV-1 infection and treatment,” Retrovirology 12:17.
[cited by applicant]
Kabat (1991) “Sequences of Proteins of Immunological Interest” National Institutes of Health, Bethesda, Md. 147:1709-1719.
[cited by applicant]
Kazane, et al. (2013) “Self-Assembled Antibody Multimers through Peptide Nucleic Acid Conjugation,” Journal of the American Chemical Society, 135(1):340-346.
[cited by applicant]
Kelly et al. (2018) “Immuno-PET detection of LAG-3 expressing intratumoral lymphocytes using the zirconium-89 radiolabeled fully human anti-LAG-3 antibody REGN3767”, Abstract in Proceedings AACR Cancer Res., 78(Suppl): …
[cited by applicant]
Klein, et al. (2012) “Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies,” mAbs 4(6):653-663.
[cited by applicant]
Kouo et al. (2015) “Galectin-3 shapes antitumor immune responses by suppressing CD8+ T cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells,” Cancer Immunol. Res. Published Online First Feb. 17, 2015…
[cited by applicant]
Kufer et al. (2004) “A revival of bispecific antibodies,” Trends in Biotech. 22(5):238-244.
[cited by applicant]
LAG3 protein [
[cited by applicant]
Lamberts et al., (2015) “ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer Before Anti-Mesothelin Antibody-Drug Conjugate Treatment”, Clinical Cancer Research, 22(7):1642-1652.
[cited by applicant]
Langer (1990) “New methods of drug delivery,” Science 249:1527-1533.
[cited by applicant]
Lecocq et al. (2019) “Noninvasive Imaging of the Immune CheckpointLAG-3 Using Nanobodies, from Development to Pre-Clinical Use”, Biomolecules, 9(10):1-19.
[cited by applicant]
Lederman et al. (1991) “A Single Amino Acid Substitution in a Common African Allele of the CD4 Molecule Ablates Binding of the Monoclonal Antibody, OKT4” Molecular Immunology 28:1171-1181.
[cited by applicant]
Legat et al. (2013) “Inhibitory receptor expression depends more dominantly on differentiation and activation than “exhaustion” of human CD8 T cells,” Frontiers in Immunol., Tumor Immunity 4:455.
[cited by applicant]
Lerner (1982) “Tapping the immunological repertoire to produce antibodies of predetermined specificity” Nature 299:592-596.
[cited by applicant]
Li and Zhu (2016) “Immuno-PET imagining using 89Zr labeled PD-L1 antibody in non-small cell lung cancer Kenograft”, Journal of Nuclear Medicine, 57(Suppl. 2):337.
[cited by applicant]
Li et al. (2007) “Metalloproteases regulate T-cell proliferation and effector function via LAG-3,” The EMBO Journal 26 (2) 494-504.
[cited by applicant]
Liang et al. (2008) “Regulatory T Cells Inhibit Dendritic Cells by LymphocyteActivation Gene-3 Engagement of MHC Class II 1,” J. Immunol. 180:5916-5926.
[cited by applicant]
Llosa et al. (2014) “The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints,” Cancer Discov. 5(1):43-51.
[cited by applicant]
Lloyd (1999) “The Art, Science and Technology of Pharmaceutical Compounding,” 8 pages.
[cited by applicant]
Macon-Lemaitre and Triebel (2005) “The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells,” Immunology 115:170-178.
[cited by applicant]
Mao et al. (2016) “Pathological a-synuclein transmission initiated by binding lymphocyte-activation gene 3,” Science 353:6307.
[cited by applicant]
Iyer et al. (2011) “Antibody Drug Conjugates—Trojan Horses in the War on Cancer”, Journal of Pharmacological and Toxicological Methods, 64(3): 207-212.
[cited by applicant]
Sugyo et al. (2013) “Evaluation of 89Zr-Labeled Human Anti-CD147 Monoclonal Antibody as a Positron Emission Tomography Probe in a Mouse Model of Pancreatic Cancer”, PLOS One, 8(4): e61230, 9 pages.
[cited by applicant]
Abaza and Atassi (1992) “Effects of Amino Acid Substitutions Outside an Antigenic Site on Protein Binding to Monoclonal Antibodies of Predetermined Specificity Obtained by Peptide Immunization: Demonstration with Region…
[cited by applicant]
Al-Lazikani et al. (1997) “Standard Conformations for the Canonical Structures of Immunoglobulins,” J. Mol. Biol. 273:927-948.
[cited by applicant]
Altschul et al. (1990) “Basic Local Alignment Search Tool,” J. Mol. Biol. 215:403-410.
[cited by applicant]
Altschul et al. (1997) “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,” Nucleic Acids Research, 25(17):3389-3402.
[cited by applicant]
Alzimami et al., “Comparison of Zr-89, I-124, and F-18 Imaging Characteristics in PET Using Gate Monte Carlo Simulations: Imaging” International Journal of Radiation Oncology, 2014, 88:502.
[cited by applicant]
Anderson et al. (2016) “Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptorswith Specialized Functions in Immune Regulation,” Immunity 44:989-1004.
[cited by applicant]
Andreae et al. (2002) “Maturation and Activation of Dendritic Cells Induced by Lymphocyte Activation Gene-3 (CD223),” J. Immunol. 168:3874-3880.
[cited by applicant]
Andreae et al. (2003) “MHC class II signal transduction in human dendritic cells induced by a natural ligand, the LAG-3 protein (CD223),” Blood 102(6):2130-2137.
[cited by applicant]
Arruebo et al. (2009) “Antibody-conjugated nanoparticles for biomedical applications,” J. of Nanomaterials, vol. 2009, Article ID 439389, 24 pgs, doi: 10.1155/2009/439389.
[cited by applicant]
Bae et al. (2014) “Trafficking of LAG-3 to the Surface on Activated T Cells vialts Cytoplasmic Domain and Protein Kinase C Signaling,” J. Immunol. 2014; 193:3101-3112.
[cited by applicant]
Barber et al. (2006) “Restoring function in exhausted CD8 T cells during chronic viral infection,” Nature 439:682-687.
[cited by applicant]
Blackburn et al. (2009) “Coregulation of CD8+ T cell exhaustion by multipleinhibitory receptors during chronic viral Infection,” Nature Immunology 10(1):29-37.
[cited by applicant]
Boerman and Oyen (2011) “Immuno-PET of Cancer: A Revival of Antibody Imaging”, Journal of Nuclear Medicine, 52(8): 1171.
[cited by applicant]
Brignone et al (2010) “First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity,” J. of Translational Medicine 8:71.
[cited by applicant]
Brignone et al. (2007) “A Soluble Form of Lymphocyte Activation Gene-3 (IMP321)Induces Activation of a Large Range of Human Effector Cytotoxic Cells,” J. Immunol. 179:4202-4211.
[cited by applicant]
Brignone et al. (2007) “IMP321 (sLAG-3) safety and T cell response potentiation using an influenza vaccine as a model antigen: A single-blind phase I study,” Vaccine 25:4641-4650.
[cited by applicant]
Brignone et al. (2007) “IMP321 (sLAG-3), an immunopotentiator for T cell responses against a HBsAg antigen in healthy adults: a single blind randomised controlled phase I study,” Journal of Immune Based Therapies and Va…
[cited by applicant]
Brignone et al. (2009) “A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma,” Clin. Cancer Res. 15(19):6225-6231.
[cited by applicant]
Brown, et al. (1996) “Tolerance to Single, but Not Multiple, Amino Acid Replacements in Antibody V, CDR2”, The Journal of Immunology, 156: 3285-3291.
[cited by applicant]
Buisson and Triebel (2005) “LAG-3 (CD223) reduces macrophage and dendritic cell differentiation from monocyte precursors,” Immunology 114:369-374.
[cited by applicant]
Camisaschi et al. (2010) “LAG-3 Expression Defines a Subset of CD4+CD25highFoxp3+ Regulatory T Cells That Are Expanded at Tumor Sites,” J. Immunol. 184:6545-6551.
[cited by applicant]
Camisaschi et al. (2014) “Alternative Activation of Human Plasmacytoid DCs In Vitro and in Melanoma Lesions: Involvement of LAG-3,” J. of Investigative Dermatology 134:1893-1902.
[cited by applicant]
Casati et al. (2006) “Soluble Human LAG-3 Molecule Amplifies the In vitro Generation of Type 1 Tumor-Specific Immunity,” Cancer Res. 66(8):4450-4460.
[cited by applicant]
Casati et al. (2008) “Human Lymphocyte Activation Gene-3 Molecules Expressed by Activated T Cells Deliver Costimulation Signal for Dendritic Cell Activation1,” J. Immunol. 180:3782-3788.
[cited by applicant]
Chang et al. (2015) “Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression”, Cell, 162:1229-1241.
[cited by applicant]
Chatterjee et al. (2016) “A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors”, Oncotarget 7(9):10215-10227.
[cited by applicant]
Chen and Chen (2014) “The effect of immune microenvironment on the progressionand prognosis of colorectal cancer,” Med. Oncol. 31:82.
[cited by applicant]
Chen and Flies (2013) “Molecular mechanisms of T cell co-stimulation and co-inhibition,” Nature Rev. Immunol. 13:227-242.
[cited by applicant]
Chen et al. (2015) “LAG-3 Negatively Regulates the Function of Intrahepatic HCV-specific CD8+ T Cells,” doi: 10.1111/jgh.13017.
[cited by applicant]
Cheson et al. (2014) “Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification,” J. Clin. Oncol. 32(27):3059-3068.
[cited by applicant]
Chun et al. (2004) “The effect of soluble LAG-3 (CD223) treatment in fetal thymic organ culture,” Biotechnology Letters 26: 1371-1377.
[cited by applicant]
Colman, et al. (1994) “Effects of amino acid sequence changes on antibody-antigen interactions”, Research in Immunology 145(1):33-36.
[cited by applicant]
Crawford et al. (2014) Molecular and Transcriptional Basis of CD4+ T Cell Dysfunction during Chronic Infection, Immunity 40:289-302.
[cited by applicant]
Creelan (2015) “Update on Immune Checkpoint Inhibitors in Lung Cancer,” Cancer Control, J. of Moffitt Cancer Center 21(1):80-89.
[cited by applicant]
De Vries “Antibody immunotherapy imaging.” Department of Medical Oncology University Medical Center Groningen, The Netherlands, 16 pages.
[cited by applicant]
De Vries (2015) “MPDL3280A-imaging-IST-UMCG”, ClinicalTrials.gov Identifier: NCT02453984, University Medical Center Groningen, 10 pages.
[cited by applicant]
Demeure et al. (2001) “T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts,” Eur. J. of Can…
[cited by applicant]
Deng et al. (2016) “Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor”, mAbs, 8(3):593-603.
[cited by applicant]
Deri et al. (2015) “p-SCN-Bn-HOPO: A Superior Bifunctional Chelator for (89)Zr ImmunoPET”, Bioconjugate Chem., 26(12) 2579-2591.
[cited by applicant]
Dijkers et al. (2010) “Biodistribution of 89Zr-trastuzumab and PETImaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer”, Clinical Pharmacology and Therapeutics, 87(5):586-592.
[cited by applicant]
Domizio et al. (2014) “Plasmacytoid Dendritic Cells in Melanoma: Can We Revert Bad into Good?” J. of Investigative Dermatology 134, 1797-1800.
[cited by applicant]
Edwards, et al. (2003) “The Remarkable Flexibility of the Human Antibody Repertoire; Isolation of Over One Thousand Different Antibodies to a Single Protein, BLyS” J. Mol. Biol. 334:103-118.
[cited by applicant]
Ehring (1999) “Hydrogen Exchange/Electrospray Ionization Mass Spectrometry Studies of Structural Features of Proteins and Protein/Protein Interactions,” Analytical Biochem. 267:252-259.
[cited by applicant]
Eisenhauer et al. (2009) “New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), ” Eur. J. Cancer 45:228-247.
[cited by applicant]
Engen and Smith (2001) “The Basics of Ion Chromatography,” Anal. Chem. 73:256A-265A.
[cited by applicant]
Ferrara, et al. (2015) “Recombinant renewable polyclonal antibodies” mAbs 7(1):32-41.
[cited by applicant]
Ferris et al. (2014) “Too Much of a Good Thing? Tim-3 and TCR Signaling in T Cell Exhaustion,” J. Immunol. 193:1525-1530.
[cited by applicant]
Flies et al (2011) “Blockade of the B7-H1/PD-1 Pathway for Cancer Immunotherapy,” Yale J. Biol. Med. 84(4):409-421.
[cited by applicant]
Foote et al. (1992) “Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops,” J. Mol. Biol. 224: 487-499.
[cited by applicant]
Fougeray et al. (2006) “A soluble LAG-3 protein as an immunopotentiator for therapeutic vaccines: Preclinical evaluation of IMP321,” Vaccine 24:5426-5433.
[cited by applicant]
Triebel et al. (2006) “A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors,” Cancer Letters 235:147-153.
[cited by applicant]
Turnis et al. (2012) “Combinatorial immunotherapy PD-1 may not be LAG-ing behind any more,” Oncolmmunology 1(7):1172-1174.
[cited by applicant]
Turnis et al. (2015) “Inhibitory receptors as targets for cancer immunotherapy,” Eur. J. Immunol. 45:1892-1905.
[cited by applicant]
Tutt et al. (1991) “Trispecific F(ab′)3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells,” J. Immunol. 147:60-69.
[cited by applicant]
Vajdos et al. (2002) “Comprehensive Functional Maps of the Antigen-binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis,” J. Mol. Biol. 320:415-428.
[cited by applicant]
Van De Watering et al. (2014) “Zirconium-89 Labeled Antibodies: A New Tool for Molecular Imaging in Cancer Patients”, Biomed Research international, Article ID 203601, 2014:1-13.
[cited by applicant]
Van Dongen, et al. (2007) “Immuno-PET: A Navigator in Monoclonal Antibody Development and Applications”, The Oncologist, 12:1379-1389.
[cited by applicant]
Vosjan, et al. (2010) “Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine” Nature Protocols, 5(4):739-743.
[cited by applicant]
Vugts, et al. (2017) “Comparison of the octadentate bifunctional chelatorDFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for 89Zr-immuno-PET”, Eur J Nucl Med Mol Imaging, 44: 286-295.
[cited by applicant]
Wang-Gillam et al. (2013) “A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma,” Invest New Drugs 31:707-713.
[cited by applicant]
Williams et al. (2015) “LAG-3 and 4-1BB identify dysfunctional antigen specificT cells in the tumor microenvironment and combinatorial LAG-3/4-1BB targeting gives synergistic tumor control,” Journal for Immuno Therapy o…
[cited by applicant]
Wolchok et al. (2009) “Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria,” Clin. Cancer Res. 15:7412-7420.
[cited by applicant]
Wong, et al. (1998) “Structural Requirements for a Specificity Switch and for Maintenance of Affinity Using Mutational Analysis of a Phage-Displayed Anti-Arsonate Antibody of Fab Heavy Chain First Complementarity-Determ…
[cited by applicant]
Woo et al. (2010) “Differential subcellular localization of the regulatory T-cell protein LAG-3 and the coreceptor CD4,” Eur J Immunol; 40(6): 1768-1777.
[cited by applicant]
Woo et al. (2012) “Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape,” Cancer Res. 72:917-927.
[cited by applicant]
Workman et al. (2002) “Cutting Edge: Molecular Analysis of the Negative Regulatory Function of Lymphocyte Activation Gene-31,” J. Immunol. 169:5392-5395.
[cited by applicant]
Workman et al. (2009) “LAG-3 Regulates Plasmacytoid Dendritic Cell Homeostasis1,” J. Immunol. 182(4):1885-1891.
[cited by applicant]
Wu et al. (1987) “Receptor-mediated in vitro gene transformation by a soluble DNA carrier system,” J. Biol. Chem. 262:4429-4432.
[cited by applicant]
Xiao and Freeman (2015) “The Microsatellite Instable Subset of Colorectal Cancer Is a Particularly Good Candidate for Checkpoint Blockade Immunotherapy,” Cancer Discovery 5:16-18.
[cited by applicant]
Xu et al. (2014) “LSECtin Expressed on Melanoma Cells Promotes TumorProgression by Inhibiting Antitumor T-cell Responses,” Cancer Res. 74(13):3418-3428.
[cited by applicant]
Yan et al. (2015) “Targeting C-type lectin receptors for cancer immunity,” Frontiers in Immunology 6:408.
[cited by applicant]
Zhai, et al. (2015) “Novel Bifunctional Cyclic Chelator for 89Zr Labeling-Radiolabeling and Targeting Properties of RGD Conjugates”, Mol. Pharmaceutics, 12:2142.
[cited by applicant]
Knight et al. (2016) “Scaling-down Antibody Radiolabeling Reactions With Zirconium-89”, Dalton Trans., 45:6343-6347.
[cited by applicant]
Josefsson et al. (2016) “Imaging Biodistribution, and Dosimetry of Radionuclide-Labeled PD-L1 Antibody in an Immunocompetent Mouse Model of Breast Cancer,” Cancer Research, 76(2):472-479.
[cited by applicant]